BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia

被引：31

作者：

Doggrell, SA ^{[1
]}

机构：

[1] Univ Queensland, Sch Biomed Sci, Doggrell Biomed Commun, Brisbane, Qld 4072, Australia

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2005年 / 14卷 / 01期

关键词：

BCR-ABL mutants; BMS-354825; chronic myeloid leukaernia; imatinib; ECE;

D O I：

10.1517/13543784.14.1.89

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The BCR-ABL tyrosine kinase inhibitor imatinib has greatly improved the outcome for patients with chronic myeloid leukaemia (CML). Unfortunately, mutations causing resistance to imatinib are leading to relapses in some patients. In addition to inhibiting the wild-type BCR-ABL, BMS-354825 inhibited 14 of 15 BCR-ABL mutants. BMS-354825 treatment of immunodeficient mice prevented the progression of the disease in mice treated with the most clinical common imatinib-resistant mutant Met351Thr. The safety and efficacy of BMS-354825 is presently being evaluated in a phase I/II clinical trial in CML patients with imatinib resistance. The frequency of clinical use of SMS-3548125 in CML patients will depend on its efficacy/safety profile in clinical trial.

引用

页码：89 / 91

页数：3

共 12 条

[1]

ANSTROM KJ, 2000, CANCER, V101, P2584

[2] SRCircumventing imatinib resistance [J].

Deininger, MWN ;

Druker, BJ .

CANCER CELL, 2004, 6 (02) :108-110

[3] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[4] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[5] Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS study [J].

Hahn, EA ;

Glendenning, GA ;

Sorensen, MV ;

Hudgens, SA ;

Druker, BJ ;

Larson, RA ;

O'Brien, SG ;

Dobrez, DG ;

Hensley, ML ;

Cella, D .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) :2138-2146

[6]

Huron DR, 2003, CLIN CANCER RES, V9, P1267

[7]

La Rosée P, 2002, CANCER RES, V62, P7149

[8] Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa [J].

Marin, D ;

Marktel, S ;

Szydlo, R ;

Klein, JP ;

Bua, M ;

Foot, N ;

Olavarria, E ;

Shepherd, P ;

Kanfer, E ;

Goldman, JM ;

Apperley, JF .

LANCET, 2003, 362 (9384) :617-619

[9] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J].

O'Brien, SG ;

Guilhot, F ;

Larson, RA ;

Gathmann, I ;

Baccarani, M ;

Cervantes, F ;

Cornelissen, JJ ;

Fischer, T ;

Hochhaus, A ;

Hughes, T ;

Lechner, K ;

Nielsen, JL ;

Rousselot, P ;

Reiffers, J ;

Saglio, G ;

Shepherd, J ;

Simonsson, B ;

Gratwohl, A ;

Goldman, JM ;

Kantarjian, H ;

Taylor, K ;

Verhoef, G ;

Bolton, AE ;

Capdeville, R ;

Druker, BJ ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shustik, C ;

Lipton, J ;

Forrest, D ;

Walker, I ;

Roy, DC ;

Rubinger, M ;

Bence-Bruckler, I ;

Kovacs, M ;

Turner, AR ;

Birgens, H ;

Bjerrum, O ;

Facon, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) :994-1004

[10] Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML [J].

O'Hare, T ;

Pollock, R ;

Stoffregen, EP ;

Keats, JA ;

Abdullah, OM ;

Moseson, EM ;

Rivera, VM ;

Tang, H ;

Metcalf, CA ;

Bohacek, RS ;

Wang, YH ;

Sundaramoorthi, R ;

Shakespeare, WC ;

Dalgarno, D ;

Clackson, T ;

Sawyer, TK ;

Deininger, MW ;

Druker, BJ .

BLOOD, 2004, 104 (08) :2532-2539

← 1 2 →